Second-generation antidepressants.
The host of newly developed antidepressant drugs offer important clinical advantages to some patients, although their promises of improved therapeutic efficacy and reduced adverse effects compared with conventional treatments are not fully realized. Increased biochemical specificity and unique mechanistic or clinical profiles render these compounds valuable in research into the pathophysiology of affective disorders and mode of action of antidepressant agents.
D000525:Alprazolam; D000657:Amoxapine / Q000494:pharmacology / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000494:pharmacology; D016642:Bupropion; D015283:Citalopram; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D008376:Maprotiline / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D009627:Nomifensine / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D011427:Propiophenones / Q000627:therapeutic use; D011437:Propylamines / Q000494:pharmacology; D012640:Seizures / Q000139:chemically induced; D012701:Serotonin / Q000378:metabolism; D014196:Trazodone / Q000627:therapeutic use; D015031:Zimeldine / Q000009:adverse effects
D000928:Antidepressive Agents; D011427:Propiophenones; D011437:Propylamines; D016642:Bupropion; D015283:Citalopram; D001569:Benzodiazepines; D009627:Nomifensine; D008376:Maprotiline; D012701:Serotonin; D015031:Zimeldine; C027299:hydroxymaprotilin; D000657:Amoxapine; D004298:Dopamine; D009638:Norepinephrine; D014196:Trazodone; D000525:Alprazolam